PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA) | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)	Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, hormone receptor-positive breast cancer, neoplasm, skin disorder	Recruiting	Phase 2	2026-08-26		NCT07222215

7 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Gateway for Cancer Research	32
Johns Hopkins University	579
Kristina A. Fanucci	2
Menarini Group	9
Stemline Therapeutics, Inc.	22
Terri Brodeur Breast Cancer Foundation	2
Translational Breast Cancer Research Consortium	19

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Dana-Farber Cancer Institute	Boston	United States	626